BBBaşak Bağcı

Başak Bağcı

*This is an algorithmically generated author record based on publicly available information.

Başak Bağcı has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diet-Derived Trimethylamine N-Oxide (TMAO) Pathway Disruption in Patients with Concurrent Alcohol Use Disorder and Smokers Persists After Alcohol Detoxification

    by Betül Rabia Erdoğan, Zinnet Şevval Aksoyalp, Çağatay Hasip, Başak Bağcı, Saliha Aksun

    Background and Purpose: Trimethylamine N-oxide (TMAO), a gut-microbiota-derived metabolite, is associated with cardiometabolic diseases, and therapeutic strategies targeting TMAO reduction are gaining interest for disease management. This study aimed to compare serum TMAO levels in patients with alcohol use disorder (AUD) and smokers versus healthy controls, and to assess changes following medically supervised alcohol detoxification.Method: Demographic data, biochemical parameters, and serum TMAO levels were analyzed. These parameters were quantified in healthy controls and patients with AUD and smokers before and after alcohol detoxification.Results: The study included thirty-four healthy controls (six females and 28 males) and thirty-three patients (five females and 28 males) with AUD and smokers. At baseline, patients demonstrated significantly lower TMAO levels but higher levels of ferritin, CRP, AST, ALT, GGT, and MCV compared to healthy controls. Following detoxification, patients exhibited a further decrease in TMAO levels (p=0.024), alongside significant improvements in hepatic enzymes (AST and GGT) and ferritin levels (p

  • The Need to Include Pregabalin in Routine Substance Screening Panels to Detect Non-Therapeutic Use and Abuse

    by Saliha Aksun, Başak Bağci, Oğuz Karalar, Murat Aksun, Barış Karadaş, Faruk Yavuz, Aslı Tuğba Esen, Mert Üğe, Figen Narin

    Pregabalin, prescribed for various neurological and psychiatric conditions, has demonstrated increasing potential for abuse. Despite its psychoactive effects and growing misuse, pregabalin remains absent from standard urine drug screening panels in Türkiye. To assess the prevalence of pregabalin abuse through comprehensive biochemistry laboratory data and to underscore the necessity of including pregabalin in routine toxicological screening protocols. This retrospective study analyzed urine drug screening results from 2019 to 2024 obtained in a tertiary hospital's biochemistry laboratory. Analysis was performed using a validated liquid chromatography system coupled with a tandem mass spectrometry method, which included pregabalin, gabapentin, and over 140 other substances. Data were stratified by year, clinical department, and co-detected substances. Urine pregabalin concentrations were statistically compared between single-use and polydrug use groups using the Mann-Whitney U-test. Pregabalin was detected in 15%-18% of analyzed urine samples annually, sometimes exceeding methamphetamine detection rates. The majority of positive cases originated from probation services and the Alcohol and Substance Use Disorder Treatment Center outpatient clinics. Notably, urine samples with co-detected substances exhibited significantly higher pregabalin concentrations (P < .05). The most frequently co-used drugs were cannabis and methamphetamines. However, a significant subgroup used pregabalin as the sole psychoactive substance. These individuals would be misclassified as "negative" in routine screening panels that exclude pregabalin. To describe this diagnostic blind spot, the term "incomplete negativity" is proposed, referring to toxicology reports that falsely appear negative due to limited panel scope, not true drug abstinence. Pregabalin abuse remains under-recognized due to current technical and regulatory limitations. Inclusion of pregabalin in routine drug panels is both feasible and urgently needed. The concept of incomplete negativity, introduced in this study, underscores the need to revise national toxicology practices and expand screening panels to include pregabalin. A multidisciplinary approach involving clinical psychiatry, medical biochemistry, and public health authorities is crucial. Recognizing this diagnostic gap is essential for effective clinical and legal responses to substance use disorders.

  • How Successful are We in the Elimination of HCV Infection in the Alcohol and Substance-Dependent Population?

    by Nesrin Türker, Banu Karaca, Hatice Burcu Açikalin Arikan, Bahar Örmen, Figen Kaptan, Başak BAĞCI, Özge Eren Korkmaz

  • The association of psychotic experiences with clinical and sociodemographic characteristics in cannabis users

    by Umut Baklaci, Ebru Aldemir, Burak Akdoner, Ozlem Kuman Tuncel, Basak Bagci, Hayriye Elbi

  • Yasadışı Madde Analizlerinde Preanalitik Evre

    by Saliha Aksun, Başak Bağcı, Leyla Demir, Furkan Oğuzhan Karalar, Murat Aksun

    Uyuşturucu ve uyarıcı madde çalışmalarında, analiz evresinin güvenliği ve doğruluğu yanında, preanalitik evrenin de laboratuvar uzmanı tarafından kontrol altında tutulması oldukça önemlidir. Bu süreçte, analizi isteyen klinik birim ile iş birliği içinde olmak ve uygun şartları, iş akışlarını birlikte planlamak en uygun yöntem olacaktır. Preanalitik evre; uygun numunenin belirlenmesi, test panelinin doğru olarak yapılandırılması, bilgi işlem sistemi ile ilgili düzenlemeler, numunelerin kimliklendirilmesi, gözetim altında örnek alınabilmesi için gerekli fiziksel düzenlemelerin kontrolü, olası hile yöntemlerinin önlenebilmesi için tedbir alınmasının sağlanması, hasta onamının alınması, numunenin güvenli transferi, örnek teslim alma ve kayıt sürecinin yapılandırılması, analiz öncesinde örneklerin güvenli saklanması süreçlerinin tamamını içermektedir.